Loading
Nuclear medicine physician who leads ENZA-p and the PSMA imaging trials shaping Australian theranostics.
Louise Emmett (St Vincent's Hospital, Sydney) was principal investigator of ENZA-p, the ANZUP trial showing that adding 177Lu-PSMA-617 to enzalutamide delays progression in castration-resistant prostate cancer, and led the PRIMARY study of PSMA PET for diagnosis. She co-leads the ANZUP theranostics programme and writes widely used guidance on PSMA PET reporting.
| Title | Journal | Year |
|---|---|---|
| [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial | Lancet Oncology | 2024 |
| The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY) | European Urology | 2021 |
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters) and the tags prostate, radioligand.
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
Shares European Urology, PSMA, PSMA PET, Prostate cancer and the tag prostate.
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters).
Shares Lutetium-177 vipivotide tetraxetan, PSMA, PSMA PET, Radioligand therapy (beta emitters) and the tag radioligand.
Shares Lutetium-177 vipivotide tetraxetan, PSMA, Radioligand therapy (beta emitters), Prostate cancer.
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/